Phase 3 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have signed the informed consent form agreeing to take part.
- Men or women aged 18 or older.
- People diagnosed with limited-stage small cell lung cancer (a specific type and stage of lung cancer) who have been assessed as unsuitable for surgery, or who have chosen not to have surgery.
- People with a good general level of physical functioning (able to carry out daily activities with little or no limitation, as assessed using a standard scale).
- People who have already received a combined chemotherapy and radiation treatment (called chemoradiotherapy) and whose cancer has not grown or spread since then.
- People with a life expectancy of more than 12 weeks.
- Men and women who agree to use appropriate contraception throughout the study.
- Women who are confirmed to not be pregnant at the start of the study, or who are confirmed to not be able to become pregnant.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose lung cancer is a mixed type, or a specific other type such as non-small cell lung cancer, sarcoma-like carcinoma, or large cell neuroendocrine carcinoma.
- People with extensive-stage small cell lung cancer (where the cancer has spread more widely).
- People whose cancer has grown or spread during or before the start of the study treatment period.
- People who have received, or are currently receiving, chemotherapy treatments other than the standard combination of platinum and etoposide for their type of lung cancer.
- People who have received any other anti-cancer treatment.
- People who have previously received, or are currently receiving, a therapy that targets a protein called B7-H3.
- People who have used traditional Chinese medicines intended to treat tumours within 2 weeks before the first study dose.
- People who have had major surgery within 4 weeks before the first study dose.
- People who have a lung condition involving inflammation or scarring of lung tissue (interstitial lung disease or non-infectious pneumonitis).
- People with a history of another primary cancer (a different cancer that started separately).
- People whose bone marrow, liver, kidneys, or other organs are not functioning well enough (confirm with trial site).
- People with serious, uncontrolled, or active heart or blood vessel problems.
- People with severe or uncontrolled diabetes.
- People with serious or poorly controlled high blood pressure.
- People who have had serious bleeding or a strong tendency to bleed within the month before joining the study.
- People who have had a serious blood clot in a vein or artery within the 3 months before joining the study.
- People who have had a serious infection within 4 weeks before joining the study.
- People who still have moderate or severe side effects from a previous cancer treatment (confirm with trial site for grading details).
- People with serious neurological or mental health conditions.
- People with a known allergy or sensitivity to the study drug (HS-200093) or similar medicines.
- People with any other condition that the study doctor believes could affect their safety or interfere with the study results.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Progression-free survival (PFS) According to RECIST v1.1 by Independent Review Committee (IRC); Overall survival (OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.